These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

110 related items for PubMed ID: 15017207

  • 1. The risk of finding focal cancer (less than 3 mm) remains high on re-biopsy of patients with persistently increased prostate specific antigen but the clinical significance is questionable.
    Zackrisson B, Aus G, Bergdahl S, Lilja H, Lodding P, Pihl CG, Hugosson J.
    J Urol; 2004 Apr; 171(4):1500-3. PubMed ID: 15017207
    [Abstract] [Full Text] [Related]

  • 2. Incidence and follow-up of patients with focal prostate carcinoma in 2 screening rounds after an interval of 4 years.
    Postma R, de Vries SH, Roobol MJ, Wildhagen MF, Schröder FH, van der Kwast TH.
    Cancer; 2005 Feb 15; 103(4):708-16. PubMed ID: 15648082
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
    Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG, Pileblad E.
    J Urol; 2003 May 15; 169(5):1720-3. PubMed ID: 12686817
    [Abstract] [Full Text] [Related]

  • 6. Population-based screening for prostate cancer by measuring total serum prostate-specific antigen in Iran.
    Hosseini SY, Moharramzadeh M, Ghadian AR, Hooshyar H, Lashay AR, Safarinejad MR.
    Int J Urol; 2007 May 15; 14(5):406-11. PubMed ID: 17511722
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ, Roobol DW, Schröder FH.
    Urology; 2005 Feb 15; 65(2):343-6. PubMed ID: 15708050
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Prostate specific antigen adjusted for transition zone epithelial volume: the powerful predictor for the detection of prostate cancer on repeat biopsy.
    Ohigashi T, Kanao K, Kikuchi E, Nakagawa K, Nakashima J, Marumo K, Murai M.
    J Urol; 2005 May 15; 173(5):1541-5. PubMed ID: 15821482
    [Abstract] [Full Text] [Related]

  • 13. Predicting unilateral prostate cancer based on biopsy features: implications for focal ablative therapy--results from the SEARCH database.
    Scales CD, Presti JC, Kane CJ, Terris MK, Aronson WJ, Amling CL, Freedland SJ, SEARCH Database Study Group.
    J Urol; 2007 Oct 15; 178(4 Pt 1):1249-52. PubMed ID: 17698131
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
    Loeb S, Nadler RB, Roehl KA, Antenor JA, Catalona WJ.
    J Urol; 2007 May 15; 177(5):1745-8. PubMed ID: 17437803
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.